What is Lexaria Bioscience Corp's earnings per share (EPS)?

Lexaria Bioscience Corp (LEXX) reported diluted earnings per share of $-0.66 for fiscal year 2025. This represents a -40.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lexaria Bioscience Corp Financials

LEXX

Source SEC Filings (10-K/10-Q) Data as of May 31, 2026 Currency USD FYE August

This page shows Lexaria Bioscience Corp (LEXX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LEXX FY2025 2026-07-13

Lexaria still operates like a development-stage company, with research spending and external financing driving economics far more than product sales.

Because FY2025 revenue of $706K produced $703K of gross profit, the weak economics are not at the product level; they come from a cost structure dominated by R&D and overhead. That shows up in cash: the FY2025 $11.9M net loss was close to the $10.5M operating cash outflow, so the reported loss translated into real cash consumption rather than mostly noncash accounting effects.

The business became more research-heavy, not more commercial: $8.2M of R&D in FY2025 exceeded revenue of $706K, which means added spending was aimed at development activity rather than servicing a larger sales base.

Funding came primarily from capital markets, not customers. With only $1.8M of cash against $10.5M of operating burn at FY2025, the balance sheet depended on new financing to keep the program moving.

Financial Health Signals

Financial health score pending refresh

We are recalculating Lexaria Bioscience Corp's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-24.54

Lexaria Bioscience Corp scores -24.54, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($14.1M) relative to total liabilities ($1.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Lexaria Bioscience Corp passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.88x

For every $1 of reported earnings, Lexaria Bioscience Corp generates $0.88 in operating cash flow (-$10.5M OCF vs -$11.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$706K

YoY+52.0%

5Y CAGR+17.5%

10Y CAGR+47.3%

Lexaria Bioscience Corp generated $706K in revenue in fiscal year 2025. This represents an increase of 52.0% from the prior year.

EBITDA

-$11.8M

YoY-107.1%

Lexaria Bioscience Corp's EBITDA was -$11.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 107.1% from the prior year.

Net Income

-$11.9M

YoY-105.4%

Lexaria Bioscience Corp reported -$11.9M in net income in fiscal year 2025. This represents a decrease of 105.4% from the prior year.

EPS (Diluted)

$-0.66

YoY-40.4%

Lexaria Bioscience Corp earned $-0.66 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 40.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$10.5M

YoY-109.4%

Lexaria Bioscience Corp generated -$10.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 109.4% from the prior year.

Cash & Debt

$1.8M

YoY-72.3%

5Y CAGR+6.9%

10Y CAGR+21.4%

Lexaria Bioscience Corp held $1.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

20M

YoY+0.0%

Lexaria Bioscience Corp had 20M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

99.6%

YoY+0.6pp

5Y CAGR+31.2pp

10Y CAGR+202.9pp

Lexaria Bioscience Corp's gross margin was 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.

Operating Margin

-1683.0%

YoY-443.9pp

10Y CAGR+11806.8pp

Lexaria Bioscience Corp's operating margin was -1683.0% in fiscal year 2025, reflecting core business profitability. This is down 443.9 percentage points from the prior year.

Net Margin

-1686.0%

YoY-437.7pp

5Y CAGR-388.4pp

10Y CAGR+11803.8pp

Lexaria Bioscience Corp's net profit margin was -1686.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 437.7 percentage points from the prior year.

Return on Equity

-398.1%

YoY-326.0pp

5Y CAGR-233.5pp

10Y CAGR-141.3pp

Lexaria Bioscience Corp's ROE was -398.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 326.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$8.2M

YoY+249.0%

5Y CAGR+84.3%

10Y CAGR+49.6%

Lexaria Bioscience Corp invested $8.2M in research and development in fiscal year 2025. This represents an increase of 249.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$25K

YoY-42.7%

Lexaria Bioscience Corp invested $25K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 42.7% from the prior year.

LEXX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$706K+52.0%	$464K+105.2%	$226K-11.4%	$255K-64.7%	$723K+129.6%	$315K
Cost of Revenue	$3K-43.6%	$5K-84.7%	$32K-56.2%	$72K-59.0%	$175K+76.4%	$99K
Gross Profit	$703K+53.1%	$459K+136.0%	$195K+6.1%	$184K-66.5%	$547K+154.1%	$215K
R&D Expenses	$8.2M+249.0%	$2.4M-35.6%	$3.7M+99.0%	$1.8M+45.9%	$1.3M+226.3%	$387K
SG&A Expenses	$4.3M+12.8%	$3.9M+25.8%	$3.1M-38.3%	$5.0M-0.2%	$5.0M+25.0%	$4.0M
Operating Income	-$11.9M-106.5%	-$5.8M+12.0%	-$6.5M+1.3%	-$6.6M-16.4%	-$5.7M	N/A
Interest Expense	N/A	$8K	$0	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	$0-100.0%	$6K+162.7%	$2K
Net Income	-$11.9M-105.4%	-$5.8M+13.0%	-$6.7M+8.3%	-$7.3M-80.5%	-$4.0M+1.4%	-$4.1M
EPS (Diluted)	$-0.66-40.4%	$-0.47+53.5%	$-1.01	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$0-100.0%	$20K	$0-100.0%	$174K0.0%	$174K0.0%	$174K-5.4%	$184K+119.0%	$84K
Cost of Revenue	$0	$0	$0	$0	$0	$0-100.0%	$3K	$0
Gross Profit	$0-100.0%	$20K	$0-100.0%	$174K0.0%	$174K0.0%	$174K-4.0%	$181K+115.7%	$84K
R&D Expenses	$971K+104.2%	$475K-29.2%	$671K-64.3%	$1.9M-30.7%	$2.7M+61.2%	$1.7M-13.7%	$2.0M+101.9%	$967K
SG&A Expenses	$1.0M+2.7%	$997K+10.4%	$902K-8.0%	$980K-18.8%	$1.2M-2.6%	$1.2M+34.9%	$919K-30.4%	$1.3M
Operating Income	-$2.0M-37.3%	-$1.5M+7.7%	-$1.6M+41.5%	-$2.7M+28.3%	-$3.8M-36.3%	-$2.8M-2.2%	-$2.7M-22.1%	-$2.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$14-99.5%	$3K+45.1%	$2K	N/A	$0	$0	$0	N/A
Net Income	-$2.0M-37.3%	-$1.4M+9.1%	-$1.6M+40.8%	-$2.7M+28.9%	-$3.8M-39.7%	-$2.7M-0.4%	-$2.7M-23.8%	-$2.2M
EPS (Diluted)	$-0.08-33.3%	$-0.06+14.3%	$-0.07	N/A	$-0.21-40.0%	$-0.15+6.3%	$-0.16	N/A

LEXX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$4.2M-52.9%	$8.9M+187.5%	$3.1M-60.6%	$7.8M-41.0%	$13.3M+369.1%	$2.8M
Current Assets	$3.5M-56.1%	$7.9M+267.1%	$2.2M-69.2%	$7.0M-43.9%	$12.4M+546.1%	$1.9M
Cash & Equivalents	$1.8M-72.3%	$6.5M+380.7%	$1.4M-76.7%	$5.8M-46.8%	$10.9M+743.9%	$1.3M
Inventory	N/A	N/A	$0-100.0%	$38K+29.6%	$30K-74.6%	$117K
Accounts Receivable	$368K+138.5%	$154K+21.9%	$127K-37.2%	$202K-41.1%	$342K+9.1%	$314K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.6M+30.1%	$1.2M+199.3%	$404K+100.5%	$201K-0.9%	$203K-41.2%	$346K
Current Liabilities	$1.5M+35.8%	$1.1M+310.6%	$268K+38.0%	$194K+26.6%	$153K-32.2%	$226K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.0M-62.8%	$8.0M+164.0%	$3.0M-61.7%	$7.9M-39.2%	$13.1M+426.3%	$2.5M
Retained Earnings	-$63.5M-23.1%	-$51.6M-12.7%	-$45.8M-17.0%	-$39.1M-22.8%	-$31.8M-14.5%	-$27.8M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$4.8M-26.3%	$6.5M+7.2%	$6.1M+44.9%	$4.2M-38.1%	$6.7M-22.3%	$8.7M-11.4%	$9.8M+10.4%	$8.9M
Current Assets	$4.1M-29.6%	$5.8M+7.6%	$5.4M+54.6%	$3.5M-40.3%	$5.8M-24.8%	$7.7M-12.5%	$8.8M+11.7%	$7.9M
Cash & Equivalents	$3.5M-31.4%	$5.1M+18.6%	$4.3M+138.6%	$1.8M-60.8%	$4.6M-29.2%	$6.5M-19.5%	$8.1M+24.3%	$6.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$49K+16.6%	$42K-52.3%	$88K-76.1%	$368K+2.9%	$358K+8.1%	$331K+25.7%	$263K+70.6%	$154K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$437K+57.8%	$277K-81.9%	$1.5M-2.9%	$1.6M-0.2%	$1.6M-17.8%	$1.9M+379.5%	$400K-66.9%	$1.2M
Current Liabilities	$383K+78.6%	$215K-85.3%	$1.5M-2.5%	$1.5M+0.4%	$1.5M-18.3%	$1.8M+512.0%	$298K-72.9%	$1.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.7M-28.2%	$6.6M+34.4%	$4.9M+64.3%	$3.0M-46.2%	$5.6M-22.3%	$7.1M-26.9%	$9.8M+21.6%	$8.0M
Retained Earnings	-$68.5M-3.0%	-$66.5M-2.2%	-$65.1M-2.5%	-$63.5M-4.4%	-$60.8M-6.7%	-$57.0M-5.0%	-$54.3M-5.2%	-$51.6M

LEXX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$10.5M-110.7%	-$5.0M+15.7%	-$5.9M-20.5%	-$4.9M-22.3%	-$4.0M-52.3%	-$2.6M
Capital Expenditures	$25K-42.7%	$43K+27.5%	$34K-31.4%	$49K	N/A	$0
Free Cash Flow	-$10.5M-109.4%	-$5.0M+15.4%	-$5.9M-20.0%	-$4.9M	N/A	-$2.6M
Investing Cash Flow	-$243K-28.9%	-$189K-11.2%	-$170K+6.1%	-$181K-193.2%	$194K+822.3%	-$27K
Financing Cash Flow	$6.0M-41.4%	$10.3M+548.9%	$1.6M+3664.4%	-$45K-100.3%	$13.4M+405.6%	$2.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$1.6M+24.4%	-$2.2M-119.9%	-$984K+62.8%	-$2.6M+26.3%	-$3.6M-139.3%	-$1.5M+45.1%	-$2.7M-44.1%	-$1.9M
Capital Expenditures	$0-100.0%	$41K	$0-100.0%	$1+200.0%	-$1-200.0%	$1-100.0%	$25K-42.7%	$43K
Free Cash Flow	-$1.6M+25.8%	-$2.2M-124.0%	-$984K+62.8%	-$2.6M+26.3%	-$3.6M-139.3%	-$1.5M+45.5%	-$2.8M-42.2%	-$1.9M
Investing Cash Flow	-$27K+49.8%	-$54K-957.2%	-$5K+96.8%	-$158K-712.0%	-$19K+30.3%	-$28K+26.2%	-$38K+45.7%	-$70K
Financing Cash Flow	$0-100.0%	$3.0M-12.4%	$3.5M	$0-100.0%	$1.7M+14311.7%	$12K-99.7%	$4.3M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LEXX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	99.6%+0.6pp	99.0%+12.9pp	86.1%+14.2pp	71.9%-3.9pp	75.7%+7.3pp	68.4%
Operating Margin	-1683.0%-443.9pp	-1239.2%+1649.3pp	-2888.5%-296.8pp	-2591.7%-1804.8pp	-786.9%	N/A
Net Margin	-1686.0%-437.7pp	-1248.3%+1698.1pp	-2946.4%-100.1pp	-2846.3%-2289.1pp	-557.2%+740.4pp	-1297.6%
Return on Equity	-398.1%-326.0pp	-72.1%+146.8pp	-218.9%-127.5pp	-91.5%-60.6pp	-30.8%+133.7pp	-164.5%
Return on Assets	-285.1%-219.7pp	-65.3%+150.8pp	-216.1%-123.3pp	-92.8%-62.4pp	-30.3%+114.1pp	-144.4%
Current Ratio	2.32-4.9	7.18-0.9	8.03-27.9	35.96-45.2	81.18+72.7	8.53
Debt-to-Equity	0.53+0.4	0.15+0.0	0.13+0.1	0.030.0	0.02-0.1	0.14
FCF Margin	-1483.9%-406.5pp	-1077.4%+1537.5pp	-2614.8%-685.1pp	-1929.8%	N/A	-831.9%

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	100.0%	N/A	100.0%0.0pp	100.0%0.0pp	100.0%+1.5pp	98.5%-1.5pp	100.0%
Operating Margin	N/A	-7259.5%	N/A	-1545.2%+610.2pp	-2155.4%-574.4pp	-1581.0%-118.1pp	-1463.0%+1159.8pp	-2622.7%
Net Margin	N/A	-7249.9%	N/A	-1549.3%+628.3pp	-2177.6%-618.3pp	-1559.3%-89.3pp	-1470.0%+1130.9pp	-2600.9%
Return on Equity	-42.0%-20.1pp	-22.0%+10.5pp	-32.5%+57.7pp	-90.2%-21.9pp	-68.3%-30.3pp	-38.0%-10.3pp	-27.7%-0.5pp	-27.2%
Return on Assets	-41.6%-19.3pp	-22.4%+4.0pp	-26.4%+38.2pp	-64.6%-8.4pp	-56.2%-24.9pp	-31.3%-3.7pp	-27.6%-3.0pp	-24.6%
Current Ratio	10.60-16.3	26.88+23.2	3.68+1.4	2.32-1.6	3.90-0.3	4.24-25.4	29.64+22.5	7.18
Debt-to-Equity	0.09+0.1	0.04-0.3	0.31-0.2	0.53+0.2	0.28+0.0	0.27+0.2	0.04-0.1	0.15
FCF Margin	N/A	-11023.4%	N/A	-1518.7%+541.1pp	-2059.7%-1198.9pp	-860.9%+634.7pp	-1495.6%+807.6pp	-2303.2%

Similar Companies

Curis CRIS

$9.1M

Aspire Biopharma Holdings Inc ASBP

$9.3M

Promis Neuroscie PMN

$113.1M

Cingulate Inc CING

$65.2M

Neuraxis Inc NRXS

$86.8M

Frequently Asked Questions

What is Lexaria Bioscience Corp's annual revenue?

Lexaria Bioscience Corp (LEXX) reported $706K in total revenue for fiscal year 2025. This represents a 52.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lexaria Bioscience Corp's revenue growing?

Lexaria Bioscience Corp (LEXX) revenue grew by 52% year-over-year, from $464K to $706K in fiscal year 2025.

Is Lexaria Bioscience Corp profitable?

No, Lexaria Bioscience Corp (LEXX) reported a net income of -$11.9M in fiscal year 2025, with a net profit margin of -1686.0%.

What is Lexaria Bioscience Corp's EBITDA?

Lexaria Bioscience Corp (LEXX) had EBITDA of -$11.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Lexaria Bioscience Corp's gross margin?

Lexaria Bioscience Corp (LEXX) had a gross margin of 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lexaria Bioscience Corp's operating margin?

Lexaria Bioscience Corp (LEXX) had an operating margin of -1683.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Lexaria Bioscience Corp's net profit margin?

Lexaria Bioscience Corp (LEXX) had a net profit margin of -1686.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Lexaria Bioscience Corp's return on equity (ROE)?

Lexaria Bioscience Corp (LEXX) has a return on equity of -398.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lexaria Bioscience Corp's free cash flow?

Lexaria Bioscience Corp (LEXX) generated -$10.5M in free cash flow during fiscal year 2025. This represents a -109.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lexaria Bioscience Corp's operating cash flow?

Lexaria Bioscience Corp (LEXX) generated -$10.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Lexaria Bioscience Corp's total assets?

Lexaria Bioscience Corp (LEXX) had $4.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lexaria Bioscience Corp's capital expenditures?

Lexaria Bioscience Corp (LEXX) invested $25K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Lexaria Bioscience Corp spend on research and development?

Lexaria Bioscience Corp (LEXX) invested $8.2M in research and development during fiscal year 2025.

How many shares does Lexaria Bioscience Corp have outstanding?

Lexaria Bioscience Corp (LEXX) had 20M shares outstanding as of fiscal year 2025.

What is Lexaria Bioscience Corp's current ratio?

Lexaria Bioscience Corp (LEXX) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.

What is Lexaria Bioscience Corp's debt-to-equity ratio?

Lexaria Bioscience Corp (LEXX) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lexaria Bioscience Corp's return on assets (ROA)?

Lexaria Bioscience Corp (LEXX) had a return on assets of -285.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lexaria Bioscience Corp's cash runway?

Based on fiscal year 2025 data, Lexaria Bioscience Corp (LEXX) had $1.8M in cash against an annual operating cash burn of $10.5M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Lexaria Bioscience Corp's Altman Z-Score?

Lexaria Bioscience Corp (LEXX) has an Altman Z-Score of -24.54, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Lexaria Bioscience Corp's Piotroski F-Score?

Lexaria Bioscience Corp (LEXX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lexaria Bioscience Corp's earnings high quality?

Lexaria Bioscience Corp (LEXX) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.